EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States

Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2235
https://www.valueinhealthjournal.com/article/S1098-3015(24)02449-5/fulltext
Title : EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02449-5&doi=10.1016/j.jval.2024.03.2235
First page :
Section Title :
Open access? : No
Section Order : 10232
Categories :
Tags :
Regions :
ViH Article Tags :